Related Experiment Video
Updated: May 16, 2026
09:56
Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice
Published on: February 14, 2021
Resistant hypertension: baroreflex stimulation as a new tool.
Jan Menne1, Jens Jordan, Silvia Linnenweber-Held
1Department of Nephrology and Hypertension, Medical School Hannover, Hannover, Germany. menne.jan@mh-hannover.de
Summary
A novel baroreflex stimulator shows promise for treating resistant hypertension, significantly lowering blood pressure. While placebo effects exist, newer devices demonstrate reduced complications, offering a potential new therapy.
Area of Science:
- Cardiology
- Biomedical Engineering
- Nephrology
Background:
- Uncontrolled hypertension is a major public health concern.
- Resistant hypertension requires innovative treatment strategies.
- Baroreflex stimulation is an emerging therapeutic approach.
Purpose of the Study:
- To evaluate the efficacy and safety of a new baroreflex stimulator for treating resistant hypertension.
- To assess the impact of baroreflex stimulation on sympathetic and vagal regulation.
- To analyze blood pressure reduction and complication rates with device generations.
Main Methods:
- Utilizing electrical field stimulation of carotid baroreceptors.
- Conducting long-term treatment studies and a double-blind Pivotal Trial.
- Comparing complication rates between first and second-generation devices.
Main Results:
- Acute attenuation of sympathetic activation and augmentation of vagal regulation observed.
- Average blood pressure reduction of 30-40/15-25 mmHg with up to 80% responders after 1 year.
- Complication rates reduced from 20-30% (first generation) to <10% (second generation).
Conclusions:
- Baroreflex stimulator therapy demonstrates significant blood pressure reduction in resistant hypertension.
- The second-generation device shows improved safety profile.
- Further controlled trials are needed, but the therapy is approved in Europe for severe resistant hypertension.
Related Concept Videos
01:18Neural Regulation of Blood Pressure
The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:18Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...